Endothelial Cell-Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure

Shogo Tamura1, Keitaro Akita2, Michael A Fifer3

  • 1Department of Biological Sciences Columbia University New York NY USA.

Insights

Plasma levels of endothelial cell (EC)-related proteins can predict major adverse cardiovascular events (MACE) and heart failure (HF) in hypertrophic cardiomyopathy (HCM) patients. This finding may improve risk stratification for better patient outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Biomarker Discovery
  • Proteomics

Background:

  • Hypertrophic cardiomyopathy (HCM) is associated with major adverse cardiovascular events (MACE) and heart failure (HF).
  • Endothelial cell (EC) dysfunction plays a role in HCM pathogenesis.
  • The prognostic significance of EC-related proteins in HCM remains unclear.

Purpose of the Study:

  • To investigate the prognostic value of plasma EC-related proteins for MACE and worsening HF in patients with HCM.
  • To develop and validate machine learning models using EC-related proteins for risk prediction in HCM.

Main Methods:

  • Prospective cohort study involving 722 patients with HCM.
  • Measurement of 90 plasma EC-related proteins at enrollment.
  • Development of machine learning models for MACE and HF prediction, validated in independent datasets.

Main Results:

  • The EC-related protein-based model achieved an AUC of 0.71 for predicting MACE and 0.71 for worsening HF.
  • High-risk groups identified by the model showed significantly increased risks of MACE and HF (P<0.001).

Conclusions:

  • Plasma EC-related proteins serve as significant predictors of MACE and worsening HF in HCM.
  • These proteins show potential as novel biomarkers for improved risk stratification in HCM.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
538
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
722
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
401
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.9K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
878
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
932